- Home
- SXTP
as 01-17-2025 4:00pm EST
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | WASHINGTON |
| Market Cap: | 2.7M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 967.9K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $10.67 | Next Earning Date: | 11-14-2024 |
| Revenue: | $462,612 | Revenue Growth: | 128.99% |
| Revenue Growth (this year): | 141.35% | Revenue Growth (next year): | 175.16% |
Latest 60 Degrees Pharmaceuticals Inc. News
SXTP Breaking Stock News: Dive into SXTP Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 01/17/2025
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 01/16/2025
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 01/15/2025
Argus Research
5 days ago
Daily – Vickers Top Insider Picks for 01/14/2025
Argus Research
6 days ago
Daily – Vickers Top Insider Picks for 01/13/2025
TipRanks
10 days ago
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study
Argus Research
10 days ago
Daily – Vickers Top Insider Picks for 01/09/2025
GlobeNewswire
11 days ago
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
Compare SXTP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SXTP 60 Degrees Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.